 |
 |
|
|
Technology | Programs | Pipeline | Collaborations | About Us | Contact Us |
 |
|
|
Alzheimer's Disease
Alzheimer's Disease
|
 |
Selective Aβ1-40 and Aβ1-42
lowering agents |
 |
MSSM |
|
|
Anti-aggregation agents |
|
|
MSSM |
|
|
|
|
Unmet Need - Alzheimer's Disease is a form of dementia and is incurable, degenerative, and terminal. There are 26 million cases of Alzheimer's Disease today, and the number may quadruple within the next 50 years. It is fast becoming a global health issue. Currently, the disease is only able to be managed. Novel drugs are needed to cure the disease.
Our Approach - Medisyn has partnered with the Mount Sinai School of Medisyn to leverage their cutting edge research by providing Medisyn with experimental data to build models for useful activity against Alzheimer's disease. Medisyn has delivered compounds that have quickly advanced through in vitro screening to in vivo studies with a high degree of bioactive specificity based on the researchers needs.
Pipeline Highlights:
Selective Aβ1-40 and Aβ1-42 lowering agents and Anti-aggregation agents
One hypothesis to explain the cause of the disease is the initiation of large-scale aggregation of amyloid plaques leading to generalized neuroinflammation. Models have been created to identify selective amyloid-beta lowering agents as well as anti-aggregation agents. |
|
|
|
|
|
|
|
|
|
 |
